Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM2-NivEnt
2024-514409-78-01Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of nivolumab and entinostat in cancer, central nervous system tumor, medulloblastoma and 11 more (2 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Dose limiting toxicity and Best response. Planned start Nov 2024; status: authorised.
02
Drugs
nivolumabentinostat
03
Conditions
cancercentral nervous system tumormedulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on 2024-514409-78-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514409-78-01.